Highlights from New York Lung Cancers Symposium 2024 by Stephen V Liu

The New York Lung Cancers Symposium 24 (NYLung24) took place on 16th of November 2024, in New York City.

The New York Lung Cancers Symposium is a prominent annual medical conference focused on advancements in the diagnosis, treatment, and research of lung cancer. It brings together leading oncologists, researchers, medical professionals, and other healthcare experts from around the world to discuss the latest clinical findings, treatment options, and emerging therapies in the field of lung cancer.

In connection to this event, Stephen V Liu shared several posts from New York Lung Cancers Symposium 2024.

Treatment options for EGFR exon 20 NSCLC

“Dr. Zosia Piotrowska overviews treatment options for EGFR exon 20 NSCLC at NYLung24. Current 1L standard is PAPILLON with amivantamab plus chemotherapy and exciting drugs in development including TKIs like zipalertinib, sunvozertinib, firmonertinib (formerly furmonertinib).”

Relative merits of different 1L EGFR regimens

“Dr. Roy Herbst at NYLung24 discusses the relative merits of different 1L EGFR regimens. Does the PFS improvement with osimertinib plus chemotherapy or amivantamab plus lazertinib over osimertinib alone justify the toxicity and impact on lifestyle? Will vary for patients.”

Biomarkers in the treatment of NSCLC

“Dr. Gregory Riely addresses waiting for biomarkers in the treatment of NSCLC at NYLung24. Can be hard to be patient but critically important to avoid giving the wrong treatment. Sequence of treatments have consequences.”

Duration of immunotherapy

“Duration of immunotherapy discussed at NYLung24 by Dr. Hossein Borghaei. In 2L, indefinite was better than 1 year in CheckMate-153 but what about 2y in 1L? Lack of definitive data but late toxicity can occur. Appealing to stop therapy if possible.”

MRD testing in lung cancer

“Dr. Charu Aggarwal at NYLung24 discusses MRD testing in lung cancer. Many ways to use these assays. Powerful prognostic tool in the preop setting. Landmark also correlates with outcomes. But how do we use the data today? Hoping we see clearance as a tool to escalate care.”

State of the art for SCLC

“Dr. Alissa Cooper summarizes the state of the art for SCLC at NYLung24. Will earlier use of immunotherapy in LS-SCLC change the natural history? Lurbinectedin has been our standard 2L but may move to maintenance. Tarlatamab will have a big impact, though pragmatic barriers.”

Current and future use of ctDNA in NSCLC

“Dr. Anne Chiang at NYLung24 discusses the current and future use of ctDNA in NSCLC. Worlds of possibilities and already making an impact in the clinic.”

KRAS in NSCLC

“Dr. Kathryn C. Arbour at NYLung24 discusses KRAS in NSCLC. Effective G12C inhibitors but lack of OS benefit when compared to docetaxel (possibly due to crossover). Still, clearly beneficial for some patients.”

Oligometastatic NSCLC

“Dr. Puneeth Iyengar at NYLung24 discusses NRG-LU002 and treating oligometastatic NSCLC. Lack of PFS and OS benefit in part related to toxicity but largely due to lack of understanding differences in biology, trajectory of spread.”

Find other posts on OncoDaily.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.